Scynexis (SCYX) Change in Accured Expenses (2013 - 2026)
Scynexis (SCYX) reported Change in Accured Expenses of -$1.4 million for Q1 2026, down 21.41% on a YoY basis from -$1.8 million in Q1 2025, and down 1195.41% quarter-over-quarter from -$109000.0 in Q4 2025.
Scynexis (SCYX) Change in Accured Expenses (2013 - 2026) Analysis & Trends
Scynexis has reported Change in Accured Expenses for 14 years, with the latest figure at -$1.4 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Accured Expenses fell 21.41% year-over-year to -$1.4 million; the trailing twelve-month figure through Mar 2026 stood at -$656000.0 (up 86.29% YoY), and the FY2025 full-year result was -$407000.0, up 89.0% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$1.4 million, down from -$109000.0 in the prior quarter.
- The five-year high for Change in Accured Expenses was $7.4 million in Q2 2023, with the low at -$5.8 million in Q1 2023.
- Historically, Change in Accured Expenses has averaged -$219058.8 across 5 years, with a median of -$109000.0 in 2025.
- The largest YoY upside for Change in Accured Expenses was 663.24% in 2022 against a maximum downside of 4991.84% in 2022.
- Scynexis' Change in Accured Expenses stood at -$2.5 million in 2022, then increased by 17.88% to -$2.0 million in 2023, then tumbled by 68.52% to -$3.5 million in 2024, then soared by 96.84% to -$109000.0 in 2025, then plunged by 1195.41% to -$1.4 million in 2026.
- The last three Change in Accured Expenses figures came in at -$1.4 million (Q1 2026), -$109000.0 (Q4 2025), and -$105000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | -144.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | -234.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | -12.70 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | -14.30 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 4.89 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 10.02 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 23.00 Mn |
| 10 | Scynexis | 225.23 Mn | 165.97 Mn | - | -1.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.41 Mn |
| Mar 31, 2026 | -1.41 Mn |
| Dec 31, 2025 | -109,000.00 |
| Dec 31, 2025 | -109,000.00 |
| Sep 30, 2025 | -105,000.00 |
| Sep 30, 2025 | -105,000.00 |
| Jun 30, 2025 | 970,000.00 |
| Jun 30, 2025 | 970,000.00 |
| Mar 31, 2025 | -1.16 Mn |
| Mar 31, 2025 | -1.16 Mn |
| Dec 31, 2024 | -3.45 Mn |
| Dec 31, 2024 | -3.45 Mn |
| Sep 30, 2024 | 1.75 Mn |
| Sep 30, 2024 | 1.75 Mn |
| Jun 30, 2024 | -1.92 Mn |
| Jun 30, 2024 | -1.92 Mn |
| Mar 31, 2024 | -79,000.00 |
| Mar 31, 2024 | -79,000.00 |
| Dec 31, 2023 | -2.05 Mn |
| Dec 31, 2023 | -2.05 Mn |